Biological treatments for severe asthma: A major advance in asthma care.

[1]  W. Busse,et al.  Anti–IL‐5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison , 2019, The Journal of allergy and clinical immunology.

[2]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[3]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[4]  C. Brightling,et al.  Asthma , 2018, The Lancet.

[5]  E. Hoffman,et al.  Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction , 2018, The Journal of clinical investigation.

[6]  E. Israel,et al.  Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.

[7]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[8]  L. Boulet,et al.  Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma , 2017, JAMA.

[9]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[10]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[11]  J. Corren,et al.  Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.

[12]  P. Gergen,et al.  Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[13]  Mike Thomas,et al.  Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.

[14]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[15]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[16]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[17]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[18]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[19]  R. Gangnon,et al.  Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. , 2012, The Journal of allergy and clinical immunology.

[20]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[21]  C. Thornton,et al.  Asthma Pathogenesis , 2012 .

[22]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[23]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[24]  M. Gill,et al.  Counterregulation between the FcεRI Pathway and Antiviral Responses in Human Plasmacytoid Dendritic Cells , 2010, The Journal of Immunology.

[25]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[26]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[27]  B. Bender,et al.  Adherence and persistence with fluticasone propionate/salmeterol combination therapy. , 2006, The Journal of allergy and clinical immunology.

[28]  S. Johnston,et al.  The September epidemic of asthma hospitalization: school children as disease vectors. , 2006, The Journal of allergy and clinical immunology.

[29]  S. Johnston,et al.  Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus , 2005, The Journal of experimental medicine.

[30]  E. Schulman,et al.  Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. , 2001, American journal of respiratory and critical care medicine.

[31]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[32]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[33]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .